Brighter has received the remaining approval for consumables related to Actiste Service in KSA
Brighter has now received the only remaining approval for consumables related to the Actiste Service from the Saudi Food and Drug Authority (SFDA) in the Kingdom of Saudi Arabia (KSA). The authorization process from the Communications and Information Technology Commission (CITC) for cellular connection is still ongoing. Before the service can be launched in KSA, Brighter will also have to finalize various internal and external go-to-market preparations, e.g. initiate relevant partnerships and ensure local data management compliance. For further background information, please see previous press release published November 2, 2020 here.
On receipt of all required authorizations and when the necessary preparations are in place, Brighter will transition to the commercialization phase in the KSA by officially launching the Actiste Service via selected distributors and directly with the end users.
For further information, please contact:
Christer Trägårdh, Acting CEO
Brighter’s Certified Adviser is Eminova Fondkommission AB, +46 (0)8 – 684 211 10, email@example.com, www.eminova.se.
About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.
This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 15:00 CET on January 25, 2021.